Oral News and Research

RSS

$High dose Vitamin D linked to high rate of fractures and falls$

High dose Vitamin D linked to high rate of fractures and falls

Many women have been regularly taking vitamin D supplements in the hope that it is good for their bones. However a new study has shown that high doses of this vitamin can actually increase the number of falls and fractures in older women.

12 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Giardia's surface proteins may work as vaccines to help prevent infections: Research scholar

The intestinal parasite Giardia lamblia changes outfits nearly as often as a fashion model on a Parisian runway. With more than 200 protein coats in its molecular wardrobe, this troublesome creature-the cause of innumerable cases of diarrheal infections each year-can change its appearance from one instant to the next, throwing the body's immune cells off track.

12 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

Gap between Hispanic and white asthma sufferers widen in the use daily medications

The gap between the proportion of black and white Americans with asthma who took an inhaled or oral medicine daily to prevent attacks grew wider between 2003 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 May 2010

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

A study to be published in the latest issue of The Cochrane Library and led by researchers at the University of Edinburgh and supported by colleagues at the Peninsula Dental School, the University of Ottawa and UCL Eastman Dental Institute, suggests that the treatment of serious gum (periodontal) disease in diabetics with Type 2 diabetes may lower their blood sugar levels.

12 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

R.I. overhauls Medicaid payments for elderly, disabled; Medicaid delays reported in Kansas

Rhode Island received a waiver from the Bush administration to revamp its Medicaid program for the elderly and disabled, despite concerns from "community health activists [who] feared that it would push some of the neediest onto waiting lists or worse — throw some poor people off the Medicaid rolls altogether.

12 May 2010

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Tianyin third-quarter revenue up 60%

Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Bionovo reports net loss of $4.7M for first-quarter 2010

Bionovo, Inc. today announced first quarter highlights and financial results for the three months ended March 31, 2010.

12 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

Isolite Systems to launch LED Smart Stick for dryfield illuminator at "The Art & Science of Dentistry" meeting

Isolite Systems, maker of innovative dental isolation technology, will debut an even brighter, more technically advanced LED Smart Stick for its award-winning Isolite dryfield illuminator during the California Dental Association's "The Art & Science of Dentistry" scientific meeting and exhibition held May 13 -16, 2010 at the Anaheim Convention Center.

11 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Oral News and Research

High dose Vitamin D linked to high rate of fractures and falls

Merck hosts R&D and Business Briefing

Giardia's surface proteins may work as vaccines to help prevent infections: Research scholar

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Gap between Hispanic and white asthma sufferers widen in the use daily medications

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

R.I. overhauls Medicaid payments for elderly, disabled; Medicaid delays reported in Kansas

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Tianyin third-quarter revenue up 60%

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Bionovo reports net loss of $4.7M for first-quarter 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Isolite Systems to launch LED Smart Stick for dryfield illuminator at "The Art & Science of Dentistry" meeting

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News